Advertisement

Topics

GSK1349572 Relative Bioavailability Study

2014-08-27 03:14:46 | BioPortfolio

Summary

This is a single-center, randomized, two part, open-label, crossover study in healthy adult subjects. Part A will evaluate the relative bioavailability of two new tablet formulations compared to the current tablet formulation of GSK1349572 at 50 mg administered as single doses each comprising of two 25 mg tablets. Pharmacokinetic samples from Part A will be analyzed and, if at least one of the new formulations meets appropriate criteria and is selected, Part B will be a single-sequence design conducted to evaluate food effect of the selected new tablet formulation at one dose level. A subset of subjects enrolled in Part A will continue in Part B. Safety evaluations and serial PK samples will be collected during each treatment period. A follow-up visit will occur 7-28 days after the last dose of study drug.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Infection, Human Immunodeficiency Virus

Intervention

GSK1349572 formulation AW, GSK1349572 formulation AX, GSK1349572 formulation AP

Location

GSK Investigational Site
Austin
Texas
United States
78744

Status

Recruiting

Source

GlaxoSmithKline

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:14:46-0400

Clinical Trials [2058 Associated Clinical Trials listed on BioPortfolio]

GSK1349572 First Time in Human Study

To determine safety, tolerability and pharmacokinetics of GSK1349572

GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study

GSK1349572 is an integrase inhibitor that is currently being evaluated for the treatment of HIV infection. The primary objective of this study is to determine whether the addition of a pr...

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers

The purpose of this study is to determine whether there is a drug interaction between GSK1349572 and the HIV protease inhibitors Tipranavir/Ritonavir (TPV/RTV).

GSK1349572 Drug Interaction Study With Efavirenz

GSK1349572 is an integrase inhibitor that is currently in Phase 2 clinical trials for the treatment of HIV infection. As GSK1349572 development progresses, it may be dosed with non-nucleo...

A Clinical Research Study for Assessing the Effectiveness of the New Integrase Inhibitor GSK1349572 in HIV-infected Persons With Prior Antiretroviral Treatment and Resistance to Raltegravir

Integrase is an enzyme produced by HIV so that the virus can multiply in the human body. GSK1349572 is a new drug in the integrase inhibitor class that prevents the enzyme from working pro...

PubMed Articles [16078 Associated PubMed Articles listed on BioPortfolio]

ADF: Abuse-Deterrent Formulation or Another Disillusioned Formulation?

Predictive Screening Tools Used in High Concentration Protein Formulation Development.

This review examines the use of predictive screening approaches in high concentration protein formulation development. In addition to the normal challenges associated with protein formulation developm...

Overcoming the Challenges of Low Drug Solubility in the Intravenous Formulation of Solithromycin.

Solithromycin is a fluoro-ketolide (a fourth-generation macrolide) antibiotic that has been undergoing clinical trials for the treatment of community acquired bacterial pneumonia. In this study, devel...

Preparation, characterization, and pharmacokinetics in swine of a florfenicol enteric formulation prepared using hot-melt extrusion technology.

The objective of this work was to manufacture an enteric formulation of florfenicol (FF) using hot-melt extrusion (HME) technology and to evaluate its in vitro dissolution and in vivo pharmacokinetics...

Noble UV protective agent for Bacillus thuringiensis based on a combination of graphene oxide and olive oil.

The focus of this study is investigating the performance of graphene oxide (GO) in the protective effect of olive oil on Bacillus thuringiensis (Bt) after being exposed to UV radiations. Biological pe...

Medical and Biotech [MESH] Definitions

Disorders in which phagocytic cells cannot kill ingested bacteria; characterized by frequent recurring infection with formulation of granulomas.

A type of viscous polysaccharide that is secreted from PLANTS. It has natural properties that are useful in the formulation of ADHESIVES.

Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.

A method of treating an ALLERGY by administering ALLERGENS, in liquid formulation or tablets, to the ORAL MUCOSA under the tongue.

A field of biological research combining engineering in the formulation, design, and building (synthesis) of novel biological structures, functions, and systems.

More From BioPortfolio on "GSK1349572 Relative Bioavailability Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Searches Linking to this Trial